Skip to Content

Sitavig Approval History

  • FDA approved: Yes (First approved April 12th, 2013)
  • Brand name: Sitavig
  • Generic name: acyclovir
  • Dosage form: Buccal Tablets
  • Company: BioAlliance Pharma SA
  • Treatment for: Cold Sores

Sitavig (acyclovir) is a mucoadhesive buccal tablet formulation of the antiviral drug acyclovir indicated for the treatment of recurrent orofacial herpes (cold sores).

Development History and FDA Approval Process for Sitavig

Apr 15, 2013Approval BioAlliance Pharma's Sitavig Receives FDA Approval for the Treatment of Herpes Labialis
Jun  1, 2012BioAlliance Pharma SA : Receivability of Sitavig US Registration Dossier (NDA) for the Treatment of Recurrent Orofacial Herpes Validated by the FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.